



► PHARMA POOL

Paris Panayiotopoulos
ARIAD NAMES PRESIDENT AND CEO

P. Panayiotopoulos

Paris Panayiotopoulos has been appointed president and CEO of Ariad, an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. Most recently, Mr.

Panayiotopoulos was president of EMD Serono. He succeeds Harvey J. Berger, M.D., Ariad's founder, chairman, and CEO.

At EMD Serono and its parent company Merck KGaA, he achieved organizational turnarounds in the United States, Japan, and Western Europe by building high-performing and trusting teams, and creating an enduring vision and strategy in each role that he served.

Douglas Ingram
CHASE PHARMACEUTICALS APPOINTS
FORMER ALLERGAN PRESIDENT AS CEO

Douglas Ingram

Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, including Alzheimer's disease, has named Douglas Ingram CEO. Mr. Ingram replaces John Siebert, who will continue as a senior advisor to the company.

Mr. Ingram brings almost 20 years of biotech, pharmaceutical and medical device leadership to Chase. Most recently, and until its acquisition by Actavis, he was president of Allergan, a global pharmaceutical company.

Dr. Jonathan Yingling
BIND THERAPEUTICS APPOINTS CHIEF
SCIENTIFIC OFFICER

Dr. Jonathan Yingling

Bind Therapeutics, a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, has named Jonathan Yingling, Ph.D., to the position of chief scientific officer.

In this role, Dr. Yingling is responsible for leading the company's research and development efforts to identify and pursue new product opportunities to provide meaningful improvements in patient care.

Dr. Yingling joins Bind from Bristol-Myers Squibb, where he was VP, oncology discovery and translational research. During his tenure at BMS, he

was responsible for the oncology research portfolio, as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology.

► BIOTECH POOL

Barry Labinger
BIOThera PHARMACEUTICAL NAMES CEO

Barry Labinger

BioThera Pharmaceutical, which is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers, has appointed Barry Labinger as CEO.

Mr. Labinger has experience in oncology drug development involving innate immune modulation, commercialization, and public market funding. Most recently, he served as executive VP and president, biosciences division, at Emergent BioSolutions, where he was responsible for all aspects of product development, manufacturing, and commercialization.

► SPECIALTY POOL

Philippe Adams
MERZ NORTH AMERICA APPOINTS VP,
MANAGED MARKETS

Philippe Adams

Merz North America (U.S. affiliate of the global Merz Pharma Group) has appointed Philippe Adams VP, managed markets. In this role, Mr. Adams is primarily responsible for developing Merz's North American market access and reimbursement strategy to enhance patient access to Merz prescription products.

Before joining Merz, Mr. Adams held the position of VP, managed markets, at Valeant Pharmaceuticals, leading the U.S. payer market access and reimbursement strategies across all business units, including neurology, dermatology, ophthalmology, and gastroenterology.

► AGENCY POOL

Rob Avery
Annie Heckenberger
DIGITAS HEALTH LIFE BRANDS ADDS
VETERAN STRATEGISTS

Rob Avery

Rob Avery joins Digitas Health LifeBrands as VP, group director, mobile strategy, building out the agency's team delivering connected health innovation and mobile apps in the health and wellness space.

He brings more than 18 years of experience, most recently he was VP of product management at PointRoll, where he was responsible for the company's mobile strategy, product offerings, and partner integrations for product lines across CPG, automotive, and retail clients.



Annie Heckenberger

Communications and branding industry veteran Annie Heckenberger brings 20 years of experience to the social strategy department at Digitas Health LifeBrands.

As VP, group director, brand communications strategy, Ms. Heckenberger is charged with leading and developing social media and content through earned and paid strategies, as well as driving social creative and design ways to help ideas travel further wherever they impact behavior.

Ms. Heckenberger brings a unique perspective to social strategy having established Red Tettemer O'Connell + Partners social practice in 2008. As the VP, Earned Media, she led the social and PR practices for the agency and implemented creative brand campaigns.

Ms. Heckenberger brings a unique perspective to social strategy having established Red Tettemer O'Connell + Partners social practice in 2008. As the VP, Earned Media, she led the social and PR practices for the agency and implemented creative brand campaigns.

► CRO POOL

Denise Kurowski
ADVANCED CLINICAL HIRES SENIOR VP

Denise Kurowski

Advanced Clinical, a full-service global CRO, functional outsourcing, and strategic talent acquisition provider, has augmented its staff with the addition of Denise Kurowski, senior VP, FSP, to its leadership team.

Ms. Kurowski brings more than 28 years of leadership and program management experience to Advanced Clinical, and is responsible for the continued growth of the functional services business.

Before joining Advanced, she was executive VP for Strategic Staffing Solutions (S3), an international IT staffing and solutions company. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0216-Pool



► BIOPHARMA POOL

Dr. Santiago Arroyo Constantine Chinoporos BOSTON PHARMACEUTICALS MAKES SENIOR APPOINTMENTS

Boston Pharmaceuticals, a new fully integrated drug development company offering an innovative alternative model for drug development commercialization, has appointed Santiago Arroyo, M.D., Ph.D., as chief medical officer, and Constantine Chinoporos, as chief business officer. Both work with senior leadership at the company to identify and partner with academic, biotechnology, and biopharmaceutical groups to acquire clinical assets at various stages of their development and bring them to market.

Dr. Arroyo joins Boston Pharmaceuticals from Pfizer, where he was senior VP and chief medical officer of biotherapeutics and pharmatherapeutics, responsible for clinical pharmacology in the areas of neuroscience, pain, rare diseases, cardiovascular, and metabolism.

Mr. Chinoporos was formally VP of global licensing and business development at Sanofi, where he was responsible for the global licensing activities.

Dr. Stephen Brannan Dr. Diana Hughes George Parker Robert Pintar Dr. A.J. Sankoh FORUM PHARMACEUTICALS EXPANDS MANAGEMENT TEAM

Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of transformative medicines to treat serious brain diseases, has made several team appointments.

Stephen Brannan, M.D., has been named VP, clinical research and medical affairs. Dr. Brannan has more than 15 years industry experience in clinical and medicals affairs. He held roles of increasing responsibility at Takeda, where he was most recently VP, CNS clinical science/PDD global therapeutic area head, with responsibility for the depression programs and other CNS projects.

Diana Hughes, M.D., has been appointed VP, pharmacovigilance and medical risk management. She brings more than 13 years of extensive pharmaceutical industry experience to Forum. Dr. Hughes was most recently VP, worldwide safety and regulatory at Pfizer, where she led a pioneering enhanced global labeling initiative.

George Parker has been named to the role of chief human resources officer. Mr. Parker has responsibility for all aspects of human resources across the organization. He has more than 25 years of broad human resources experience in life-science and pharmaceutical companies. Before joining Forum, Mr. Parker served as VP, global human resources at Molecular Devices.

Robert Pintar has been named VP, supply chain operations. With more than 25 years of experience in the biotechnology and pharmaceutical industry for both large and small companies, he was most recently VP, supply chain, for Cubist Pharmaceuticals, where he was instrumental in building a supply chain organization that successfully launched new products in the United States and Europe.

A.J. Sankoh, Ph.D., has been appointed VP, biostatistics and statistical programming. Dr. Sankoh has more than 20 years of extensive experience in the biopharmaceutical industry, supporting drug development, from discovery to post-marketing. Most recently he was VP, biostatistics of clinical informatics at Synageva Biopharma.

Michelle Carpenter Dr. Prabha Ibrahim AFFERENT PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM

Afferent Pharmaceuticals, a developer of small molecule compounds for the treatment of poorly managed and common neurogenic disorders, has appointed Michelle Carpenter, VP of regulatory affairs and project management, and Prabha Ibrahim, Ph.D., as chief technology officer.

Ms. Carpenter brings 25 years of biopharmaceutical experience in regulatory strategy and operations in support of drug development and commercialization. She possesses a proven track record for obtaining global regulatory approvals, particularly in the respiratory field. Before joining Afferent, she held senior positions at Acucela.

Dr. Ibrahim brings more than 23 years of experience in drug discovery and development.

► BIOTECH POOL

William McCarthy IGNYTA NAMES CHIEF BUSINESS OFFICER

Ignyta, a precision oncology biotechnology company, has named William McCarthy to the newly created role of chief business officer.

Mr. McCarthy was most recently VP, corporate

and business development, at Foundation Medicine (FMI), a position he held since April 2014.

Dr. David Roth SYROS PHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER

Syros Pharmaceuticals has named David Roth, M.D., an industry leader in oncology and hematology drug development, as its first chief medical officer. Dr. Roth is charged with providing strategic and operational leadership for all the company's clinical development activities and functions. Syros is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases. He served most recently as executive VP and chief medical officer of Infinity Pharmaceuticals.

Dr. Srdjan (Serge) Stankovic ACADIA APPOINTS EXECUTIVE VP, HEAD OF R&D

Acadia Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, has appointed Srdjan (Serge) Stankovic, M.D., as executive VP, head of research and development. With a background in clinical and academic psychiatry, Dr. Stankovic brings more than 20 years of executive level experience in drug development and clinical and medical affairs.


Dr. Stankovic most recently served as senior VP of clinical development and medical affairs, Alkermes.

► TECHNOLOGY POOL

Kristofer Spahr YOURENCORE BOLSTERS STAFF

YourEncore, which helps firms in the life-sciences, consumer products, and food sciences industries solve complex innovation, compliance, and productivity challenges, has named Kristofer Spahr as VP, solution development and delivery.

Mr. Spahr is responsible for expanding the company's suite of consulting services and managed services.

A 27-year veteran of the life-sciences industry, Mr. Spahr brings to YourEncore a strong background in regulatory process engineering and regulatory IT. 

TO **SAVE 15%**
USE CODE:
XP2106PV

ePharma

The Art and Science of Innovative Digital Strategy

FEBRUARY 29TH – MARCH 2ND, 2016 | Sheraton Times Square, New York City

THE EVENT WHERE LEADERS COME TOGETHER TO
TRANSFORM STRATEGY AND ADAPT TO EVOLVING
CUSTOMER AND INFLUENCER BASES.

Seize the opportunities of digital health trends and
disruptive innovation.



Matthew Zachary, Founder/CEO, Chief Product Officer, Instapeer; Exec. Producer, **The Stupid Cancer Show**



Judy Sowards, Head of Corporate Digital Strategy, **Pfizer**



Jane McGonigal, PhD, New York Times Bestselling Author of **SuperBetter**



Deb O'Brien, Chief Marketing Officer, **Mylan Pharmaceuticals**



Tom McCourt, Chief Commercial Officer, **Ironwood Pharmaceuticals**



Stefani Klaskow, Head of Industry Healthcare, **Google**



Meredith Guerriero, Director, **Facebook Health**

www.ePharmaSummit.com

 [@epharmasummit](https://twitter.com/epharmasummit) | [#epharmasummit](https://twitter.com/epharmasummit)